100 related articles for article (PubMed ID: 29310106)
1. Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.
Dong B; Dai G; Ding Y; Wang B; Zhang S
Int Immunopharmacol; 2018 Feb; 55():306-311. PubMed ID: 29310106
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.
Dong B; Sun L; Wu X; Zhang P; Wang L; Wei H; Zhou L; Hu X; Yu Y; Hua S; Wang L
Cancer Immunol Immunother; 2010 Jun; 59(6):899-908. PubMed ID: 20087582
[TBL] [Abstract][Full Text] [Related]
3. [Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].
Dong B; Dai G; Qi Z; Yang G; Lu J; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1673-7. PubMed ID: 24273276
[TBL] [Abstract][Full Text] [Related]
4. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
5. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand DNA enhances a vaccination effect by coadministered DNA encoding a tumor antigen through augmenting production of antibody against the tumor antigen.
Zhong B; Ma G; Sato A; Shimozato O; Liu H; Li Q; Shingyoji M; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
J Immunol Res; 2015; 2015():743828. PubMed ID: 25759847
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
[TBL] [Abstract][Full Text] [Related]
9. Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.
Dong B; Wang L; Nie S; Li X; Xiao Y; Yang L; Meng X; Zhao P; Cui C; Tu L; Lu W; Sun W; Yu Y
Vaccine; 2018 Dec; 36(52):8148-8157. PubMed ID: 30449633
[TBL] [Abstract][Full Text] [Related]
10. Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.
Kraśko JA; Žilionytė K; Darinskas A; Strioga M; Rjabceva S; Zalutsky I; Derevyanko M; Kulchitsky V; Lubitz W; Kudela P; Miseikyte-Kaubriene E; Karaman O; Didenko H; Potebnya H; Chekhun V; Pašukonienė V
Oncol Rep; 2017 Jan; 37(1):171-178. PubMed ID: 27878261
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
13. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
Sun J; Zhang J; Hu H; Qin H; Liao X; Wang F; Zhang W; Yin Q; Su X; He Y; Li W; Wang K; Li Q
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3255-3268. PubMed ID: 34291357
[TBL] [Abstract][Full Text] [Related]
15. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X
Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684
[TBL] [Abstract][Full Text] [Related]
16. [Tumor cell lysate with low content of HMGB1 enhances immune response of dendritic cells against lung cancer in mice].
Pan Z; Li S; Wang Y; Liu H; Gui L; Dong B
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):906-914. PubMed ID: 37439162
[TBL] [Abstract][Full Text] [Related]
17. The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model.
Dietrich A; Stockmar C; Endesfelder S; Guetz A; Aust G
J Cancer Res Clin Oncol; 2012 Jun; 138(6):901-6. PubMed ID: 22322363
[TBL] [Abstract][Full Text] [Related]
18. Experimental study of the efficacy of combined use of cancer vaccine and interferon.
Potebnya GP; Kudryavets YY; Lisovenko GS; Cheremshenko NL; Voeykova IM; Trokhimenko NV; Symchich TV; Evstrateyva LM
Exp Oncol; 2007 Jun; 29(2):102-5. PubMed ID: 17704740
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes.
Dong B; Dai G; Xu L; Zhang Y; Ling L; Sun L; Lv J
Mol Med Rep; 2014 Dec; 10(6):2827-34. PubMed ID: 25310154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
